<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PREGABALIN</span><br/><span class="topboxtradename">Lyrica<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">analgesic</span>; <span class="classification">anticonvulsant</span>; <span class="classification">anxiolytic</span>; <span class="classification">gaba-analog</span><br/><b>Prototype: </b>Gabapentin<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule V<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Pregabalin is an analog of gamma-aminobutyric acid (GABA). It is structurally related to gabapentin, but shows greater potency
         in pain and seizure disorders (310 times greater). The exact mechanism of action of pregabalin as an antiseizure agent
         is unknown. It increases neuronal GABA levels and reduces calcium currents in the calcium channels of neurons; this may account
         for its control of pain and anxiety.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Has analgesic, anti-anxiety, and anticonvulsant properties.</p>
<h1><a name="uses">Uses</a></h1>
<p>Management of neuropathic pain associated with diabetic peripheral neuropathy, adjunctive therapy for adult patients with
         partial-onset seizures, management of postherpetic neuralgia.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of generalized anxiety disorders, treatment of social anxiety disorder, treatment of moderate pain.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to pregabalin or gabapentin; alcohol. Safety and efficacy in children not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment or failure, hemodialysis; elderly; lactation; pregnancy (category C); congestive heart failure, NYHA (Class
         III or IV) cardiac status.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Neuropathic Pain (Diabetic Peripheral Neuropathy)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50100 mg t.i.d.<br/><br/><span class="indicationtitle">Partial-Onset Seizures</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initial dose <img src="../images/special/lesserorequal.gif"/> 75 mg b.i.d or 50 mg t.i.d; may increase to 300 mg b.i.d. or
               200 mg t.i.d.<br/><br/><span class="indicationtitle">Postherpetic Neuralgia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initial dose 75 mg b.i.d. or 50 mg t.i.d; may increase to 150300 mg b.i.d. or 100200 mg t.i.d.<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/><b>PO</b> Cl<sub>cr</sub> 3060 mL/min: 75300 mg/d  given in 2 or 3 divided doses.<br/><b>PO</b> Cl<sub>cr</sub> 1530 mL/min: 25150 mg/d given in 1 or 2 divided doses.<br/><b>PO</b> Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Dosage reduction is required with renal dysfunction.</li>
<li>Drug should not be abruptly stopped; discontinue by tapering over a minimum of 1 wk.</li>
<li>Give a supplemental dose immediately following dialysis.</li>
<li>Store at 15°30° C (59° 86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span>
<span class="speceff-common">Accidental injury,</span> flu syndrome, pain.  <span class="typehead">CNS:</span> Abnormal gait, amnesia, <span class="speceff-common">ataxia,</span> confusion, <span class="speceff-common">dizziness,</span> euphoria, headache, incoordination, myoclonus, nervousness, neuropathy, <span class="speceff-common">somnolence,</span> speech disorder, abnormal thinking, tremor, twitching, vertigo. <span class="typehead">CV:</span> Chest pain. <span class="typehead">GI:</span> Constipation, dry mouth, flatulence, increased appetite, vomiting. <span class="typehead">GU:</span> Urinary incontinence. <span class="typehead">Metabolic/Nutritional:</span> Edema, facial edema, hypoglycemia, <span class="speceff-common">peripheral edema, weight gain</span>.  <span class="typehead">Musculoskeletal:</span> Back pain, myasthenia.  <span class="typehead">Respiratory:</span> Bronchitis, dyspnea. <span class="typehead">Special senses:</span> Abnormal vision, <span class="speceff-common">blurry vision, diplopia.</span>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Concomitant use with <span class="classification">thiazolidinediones</span> may exacerbate weight gain and fluid retention.  
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 90% bioavailability. <span class="typehead">Peak:</span> 1.5 h. <span class="typehead">Metabolism:</span> Negligible. <span class="typehead">Elimination:</span> Primarily eliminated in the urine. <span class="typehead">Half-Life:</span> 6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for weight gain, peripheral edema, and S&amp;S of heart failure, especially with concurrent thiazolidinedione (e.g., rosiglitazone)
            therapy. 
         </li>
<li>Lab tests: Baseline and periodic kidney function tests; periodic platelet counts; CPK if rhabdomyolysis is suspected.</li>
<li>Monitor diabetics for increased incidences of hypoglycemia.</li>
<li>Withhold drug and notify physician if rhabdomyolysis is suspected</li>
<li>Supervise ambulation especially when other CNS drugs are used concurrently.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Report any of the following to a health care provider: changes in vision (i.e., blurred vision); dizziness and incoordination;
            unexplained muscle pain, weakness, or tenderness; weight gain and swelling of the extremities. 
         </li>
<li>Avoid alcohol consumption while taking this drug.</li>
<li>Inform your physician if you plan to become pregnant or father a child.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>